"Ribavirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
| Descriptor ID |
D012254
|
| MeSH Number(s) |
D13.570.800.790
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribavirin".
Below are MeSH descriptors whose meaning is more specific than "Ribavirin".
This graph shows the total number of publications written about "Ribavirin" by people in this website by year, and whether "Ribavirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 2 | 4 | 6 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 5 | 2 | 7 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 4 | 5 |
| 2010 | 3 | 2 | 5 |
| 2011 | 3 | 6 | 9 |
| 2012 | 7 | 0 | 7 |
| 2013 | 10 | 1 | 11 |
| 2014 | 6 | 6 | 12 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Ann Hepatol. 2023 Mar-Apr; 28(2):100899.
-
Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency. J Infect Dis. 2022 11 11; 226(10):1781-1789.
-
Hepatitis E Virus Infection in Cancer Patients. Transplant Cell Ther. 2022 11; 28(11):788.e1-788.e5.
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
-
Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro. Can J Physiol Pharmacol. 2021 May; 99(5):449-460.
-
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021 Apr; 70(4):733-742.
-
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 07; 37(7):3299-3310.
-
Reply to Jain et al. Clin Infect Dis. 2019 11 27; 69(12):2235-2236.
-
Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2019 05 02; 68(10):1641-1649.
-
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol. 2019 02; 114(2):250-257.